 Mark Manzano
Concepts (142)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 8, Human | 6 | 2022 | 98 | 1.890 |
Why?
| | Lymphoma, Primary Effusion | 4 | 2022 | 20 | 1.670 |
Why?
| | RNA, Viral | 5 | 2019 | 127 | 1.660 |
Why?
| | Dengue Virus | 7 | 2016 | 13 | 1.570 |
Why?
| | MicroRNAs | 5 | 2019 | 387 | 0.960 |
Why?
| | Oncogenes | 2 | 2019 | 60 | 0.750 |
Why?
| | Replicon | 4 | 2016 | 6 | 0.650 |
Why?
| | Host-Pathogen Interactions | 4 | 2019 | 144 | 0.640 |
Why?
| | Virus Latency | 2 | 2025 | 53 | 0.640 |
Why?
| | Genes, Essential | 2 | 2018 | 11 | 0.620 |
Why?
| | Protease Inhibitors | 2 | 2016 | 61 | 0.550 |
Why?
| | Small Molecule Libraries | 2 | 2016 | 67 | 0.540 |
Why?
| | Virus Replication | 4 | 2016 | 150 | 0.530 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 857 | 0.470 |
Why?
| | 3' Untranslated Regions | 2 | 2014 | 55 | 0.460 |
Why?
| | High-Throughput Screening Assays | 2 | 2016 | 38 | 0.460 |
Why?
| | Actins | 1 | 2015 | 115 | 0.460 |
Why?
| | Drug Discovery | 2 | 2016 | 93 | 0.440 |
Why?
| | Molecular Biology | 1 | 2014 | 27 | 0.430 |
Why?
| | Mutagenesis | 1 | 2014 | 61 | 0.430 |
Why?
| | Serine Endopeptidases | 1 | 2014 | 50 | 0.420 |
Why?
| | Recombination, Genetic | 1 | 2014 | 109 | 0.420 |
Why?
| | Saccharomyces cerevisiae | 1 | 2014 | 176 | 0.400 |
Why?
| | Protein Biosynthesis | 2 | 2011 | 258 | 0.380 |
Why?
| | Herpesvirus 4, Human | 2 | 2025 | 43 | 0.380 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2011 | 7 | 0.360 |
Why?
| | Cell Line, Tumor | 4 | 2022 | 1470 | 0.360 |
Why?
| | HEK293 Cells | 4 | 2019 | 229 | 0.320 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 990 | 0.300 |
Why?
| | B-Lymphocytes | 2 | 2025 | 184 | 0.250 |
Why?
| | Cell Line | 5 | 2019 | 1030 | 0.250 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2019 | 202 | 0.250 |
Why?
| | Germinal Center | 1 | 2025 | 30 | 0.230 |
Why?
| | Rhadinovirus | 1 | 2025 | 22 | 0.230 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2025 | 221 | 0.200 |
Why?
| | Viral Proteins | 2 | 2014 | 164 | 0.200 |
Why?
| | Cell Line, Transformed | 1 | 2022 | 74 | 0.200 |
Why?
| | bcl-2-Associated X Protein | 1 | 2022 | 58 | 0.200 |
Why?
| | Cell Proliferation | 2 | 2025 | 1023 | 0.190 |
Why?
| | Molecular Sequence Data | 2 | 2015 | 778 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 129 | 0.190 |
Why?
| | Binding Sites | 3 | 2016 | 377 | 0.170 |
Why?
| | Thalidomide | 2 | 2019 | 377 | 0.160 |
Why?
| | Cell Survival | 2 | 2018 | 612 | 0.150 |
Why?
| | Sarcoma, Kaposi | 1 | 2019 | 76 | 0.150 |
Why?
| | Casein Kinase Ialpha | 1 | 2018 | 1 | 0.150 |
Why?
| | Interferon Regulatory Factors | 1 | 2018 | 18 | 0.150 |
Why?
| | Thiophenes | 1 | 2018 | 38 | 0.150 |
Why?
| | Humans | 11 | 2022 | 52483 | 0.150 |
Why?
| | Luciferases, Renilla | 3 | 2016 | 4 | 0.150 |
Why?
| | Piperazines | 1 | 2018 | 118 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2018 | 117 | 0.140 |
Why?
| | Cell Cycle | 1 | 2018 | 230 | 0.140 |
Why?
| | Pyridines | 1 | 2018 | 132 | 0.140 |
Why?
| | Apoptosis | 1 | 2022 | 1119 | 0.140 |
Why?
| | Pyrimidines | 1 | 2018 | 199 | 0.130 |
Why?
| | Flavivirus | 1 | 2016 | 1 | 0.130 |
Why?
| | Antiviral Agents | 2 | 2016 | 178 | 0.130 |
Why?
| | Peptide Hydrolases | 1 | 2016 | 63 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 334 | 0.120 |
Why?
| | Genetic Heterogeneity | 1 | 2015 | 20 | 0.120 |
Why?
| | Molecular Mimicry | 1 | 2015 | 38 | 0.120 |
Why?
| | Species Specificity | 1 | 2015 | 192 | 0.120 |
Why?
| | Recombinant Proteins | 2 | 2014 | 483 | 0.120 |
Why?
| | Cell Transformation, Viral | 1 | 2014 | 25 | 0.120 |
Why?
| | Animals | 8 | 2025 | 13505 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2015 | 100 | 0.110 |
Why?
| | Argonaute Proteins | 1 | 2014 | 12 | 0.110 |
Why?
| | Viral Nonstructural Proteins | 2 | 2016 | 61 | 0.110 |
Why?
| | Amodiaquine | 1 | 2014 | 1 | 0.110 |
Why?
| | Genes, ras | 1 | 2014 | 43 | 0.110 |
Why?
| | Transformation, Genetic | 1 | 2014 | 17 | 0.110 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2014 | 40 | 0.110 |
Why?
| | Antimalarials | 1 | 2014 | 32 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2014 | 87 | 0.110 |
Why?
| | Plasmids | 1 | 2014 | 163 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2014 | 119 | 0.100 |
Why?
| | Virus Internalization | 1 | 2013 | 20 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 128 | 0.100 |
Why?
| | Caenorhabditis elegans | 1 | 2014 | 139 | 0.100 |
Why?
| | Oxidoreductases | 1 | 2013 | 59 | 0.100 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 461 | 0.100 |
Why?
| | DNA Repair | 1 | 2014 | 195 | 0.100 |
Why?
| | Conserved Sequence | 1 | 2011 | 53 | 0.090 |
Why?
| | Nucleic Acid Conformation | 1 | 2011 | 85 | 0.090 |
Why?
| | Fibroblasts | 1 | 2013 | 355 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 505 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2014 | 1229 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2014 | 405 | 0.080 |
Why?
| | Base Sequence | 1 | 2011 | 640 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2010 | 108 | 0.080 |
Why?
| | Mice | 5 | 2025 | 5949 | 0.080 |
Why?
| | Temperature | 1 | 2010 | 183 | 0.080 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2019 | 96 | 0.070 |
Why?
| | Time Factors | 1 | 2014 | 2968 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2025 | 879 | 0.070 |
Why?
| | Algorithms | 1 | 2011 | 672 | 0.070 |
Why?
| | Viral Plaque Assay | 2 | 2016 | 4 | 0.060 |
Why?
| | West Nile virus | 2 | 2016 | 5 | 0.060 |
Why?
| | Tumor Virus Infections | 1 | 2025 | 48 | 0.060 |
Why?
| | Herpesviridae Infections | 1 | 2025 | 57 | 0.060 |
Why?
| | Genes, Reporter | 2 | 2013 | 88 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2025 | 1567 | 0.040 |
Why?
| | Male | 2 | 2025 | 26761 | 0.040 |
Why?
| | Female | 2 | 2025 | 28171 | 0.040 |
Why?
| | Cullin Proteins | 1 | 2019 | 5 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 1884 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 108 | 0.040 |
Why?
| | Endopeptidases | 1 | 2019 | 66 | 0.040 |
Why?
| | Ikaros Transcription Factor | 1 | 2018 | 5 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 46 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 186 | 0.040 |
Why?
| | RNA Interference | 1 | 2018 | 181 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 213 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 133 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 326 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 346 | 0.030 |
Why?
| | Fluorescence | 1 | 2016 | 39 | 0.030 |
Why?
| | Models, Biological | 1 | 2019 | 735 | 0.030 |
Why?
| | Models, Molecular | 1 | 2016 | 348 | 0.030 |
Why?
| | Kinetics | 1 | 2016 | 626 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 10 | 0.030 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 16 | 0.030 |
Why?
| | Pancreatic Ducts | 1 | 2014 | 13 | 0.030 |
Why?
| | Genes, p53 | 1 | 2014 | 52 | 0.030 |
Why?
| | Protein Interaction Mapping | 1 | 2014 | 37 | 0.030 |
Why?
| | Cricetinae | 1 | 2014 | 194 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 146 | 0.030 |
Why?
| | Oxidoreductases Acting on Sulfur Group Donors | 1 | 2013 | 3 | 0.030 |
Why?
| | Luciferases | 1 | 2013 | 48 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2014 | 284 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2013 | 97 | 0.030 |
Why?
| | Autophagy | 1 | 2013 | 193 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 1671 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 871 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 566 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2014 | 1132 | 0.020 |
Why?
| | Vero Cells | 1 | 2010 | 44 | 0.020 |
Why?
| | Genes, Viral | 1 | 2010 | 39 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 82 | 0.020 |
Why?
| | Protein Stability | 1 | 2010 | 45 | 0.020 |
Why?
| | Mutation | 1 | 2014 | 1347 | 0.020 |
Why?
|
|
Manzano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|